Gilead’s total revenue for Q2 increased 1% to $6.3 billion compared to Q2 in 2021. Overall, the company exceeded both its own expectations and the predictions of market analysts for the second quarter.
https://www.pharmalive.com/wp-content/uploads/2022/04/Gileads-Veklury-Becomes-First-FDA-Approved-COVID-19-Treatment-for-Young-Children-BioSpace-4-25-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-03 09:22:172022-08-03 10:50:59Revenue drop for Gilead’s COVID-19 antiviral indicative of waning pandemic returns
